ACTION

The America Project Proudly Sponsors A Concert for Liberty Benefit for Doc Pete Chambers and The A-TEAM Join us!

Retrieved on: 
Martedì, Ottobre 10, 2023
Life, Liberty and the pursuit of Happiness, Doc, Pursuit, PEOPLE, Happiness, Veteran, Woman, The Pursuit of Happiness, Blood, ACTION, Letter, Human, Nightclub

A letter from Doc Chambers:

Key Points: 
  • A letter from Doc Chambers:
    This event is being held to support ACTION on the border.
  • NOT some self aggrandizing, "patting on the back" event, nor paid speakers brought into some grand venue to rub elbows with famous people.
  • This is a "WE THE PEOPLE" run operation to continue support for the plain folks on the border protecting everything that is dear to the American character.
  • I opted to hold it at a venue representing the service men and women who have fought in foreign wars.

Monteverde & Associates PC and Kahn Swick & Foti Announce Proposed Class Action Settlement on Behalf of Holders of GW Pharmaceuticals PLC American Depositary Shares

Retrieved on: 
Sabato, Settembre 16, 2023
Judgement, Allocation, Internet, District court, Notice, Leading Counsel, Court, WITH, TIME, Prejudice, Plan, Lawsuit, GW, OR, AND, PARTIES, Certification, Hearing, CLASS, ACTION, PLC, ALL, THIS, Dismissal, Defendant, Counsel, Plaintiff, Class Action, Settlement, Security (finance)

TO: RECORD AND BENEFICIAL HOLDERS OF GW PHARMACEUTICALS, PLC.

Key Points: 
  • TO: RECORD AND BENEFICIAL HOLDERS OF GW PHARMACEUTICALS, PLC.
  • THE PARTIES TO A SHAREHOLDER CLASS ACTION SUIT CONCERNING THE MERGER HAVE AGREED TO A PROPOSED SETTLEMENT.
  • Settlement Class Members should check the Settlement Class website in advance of the Final Approval Hearing to determine whether that hearing instead will occur via a remote link.
  • All Members of the Settlement Class who do not timely and validly request exclusion from the Settlement Class will be bound by any judgment entered in the Litigation pursuant to the Stipulation of Settlement.

Hyperfine, Inc. Reports Second Quarter 2023 Financial Results

Retrieved on: 
Lunedì, Agosto 14, 2023
Stroke, Diagnosis, MRI, Research, Baozou Big News Events, FDA, PMR, Observational study, Patient, ACTION, News, Marketing, Pharmaceutical industry, Video game, Reinsurance, Cryptocurrency, Hyperfine structure

Gross margin for the second quarter of 2023 was $1.44 million, compared to $(0.17) million in the second quarter of 2022.

Key Points: 
  • Gross margin for the second quarter of 2023 was $1.44 million, compared to $(0.17) million in the second quarter of 2022.
  • Research and development expenses for the second quarter of 2023 were $5.33 million, compared to $7.27 million in the second quarter of 2022.
  • Sales, general, and administrative expenses for the second quarter of 2023 were $7.81 million, compared to $15.76 million in the second quarter of 2022.
  • ET on Monday, August 14, 2023, to discuss its second quarter 2023 financial results and provide a business update.

Wolf Popper LLP Announces Proposed Settlement in the Advant-e Stockholder Litigation

Retrieved on: 
Venerdì, Agosto 11, 2023
Agreement, Prejudice, Fee, Effective date, Dubrovka, Dubrovsky Settlement Administrative Okrug, Dubrovsky District, Bryansk Oblast, Reverse stock split, DE, Service award, Settlement, Episcopal conference, Notice, Action, CLASS, Court, ARE, ACTION, Tobacco, Insurance, Pharmaceutical industry, Allocation, Defendant, Plaintiff

YOU ARE ALSO NOTIFIED that, after arm's-length negotiations, Peter J. Kreher ("Plaintiff"), on behalf of himself and the Settlement Class, has reached a proposed settlement with Defendants Advant-e, Jason Wadzinski, and Jason Boone (the "Defendants") for $896,973 in cash (the "Settlement").

Key Points: 
  • YOU ARE ALSO NOTIFIED that, after arm's-length negotiations, Peter J. Kreher ("Plaintiff"), on behalf of himself and the Settlement Class, has reached a proposed settlement with Defendants Advant-e, Jason Wadzinski, and Jason Boone (the "Defendants") for $896,973 in cash (the "Settlement").
  • This Summary Notice advises potential Settlement Class Members of information about the Action and the proposed Settlement.
  • Settlement Class Members do not have to submit a claim form to receive a payment from the Settlement.
  • All questions about this Notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Settlement Administrator or Plaintiff's Counsel.

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Giovedì, Agosto 3, 2023
Toxic leukoencephalopathy, Cancer, Neuro, Action, Patient, ACTION, Human, Reiterate, Conference, ONC201, Pharmaceutical industry

DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an operational update.
  • Chimerix reported a net loss of $18.6 million, or $0.21 per basic and diluted share, for the second quarter of 2023.
  • Research and development expenses decreased to $16.9 million for the second quarter of 2023, compared to $18.0 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss second quarter 2023 financial results and provide a business update today at 8:30 a.m.

Monteverde & Associates PC Announces Proposed Class Action Settlement on Behalf of All Holders of Anworth Mortgage Asset Corporation Common Stock

Retrieved on: 
Venerdì, Luglio 14, 2023
Agreement, Lis pendens, ALL, YOU, Class, Superior court, OR, AND, PARTIES, Class Action, Settlement, Compromise, Episcopal conference, Hearing, COMMON, CLASS, Court, WITH, Plaintiff, ACTION, Security (finance), Anworth Mortgage Asset Corporation

THE PARTIES TO A SHAREHOLDER CLASS ACTION SUIT CONCERNING THE MERGER HAVE AGREED TO A PROPOSED SETTLEMENT.

Key Points: 
  • THE PARTIES TO A SHAREHOLDER CLASS ACTION SUIT CONCERNING THE MERGER HAVE AGREED TO A PROPOSED SETTLEMENT.
  • YOU MAY BE ENTITLED TO COMPENSATION AS A RESULT OF THE PROPOSED SETTLEMENT IN THE ACTION CAPTIONED:
    YOU ARE HEREBY NOTIFIED, pursuant to California Code of Civil Procedure Section 382 and an Order of the Court, that the above-captioned action has been provisionally certified as a class action and that a settlement for $3,000,000 has been proposed (the "Settlement").
  • IF YOU ARE A MEMBER OF THE CLASS DESCRIBED ABOVE, YOUR RIGHTS WILL BE AFFECTED BY THIS SETTLEMENT.
  • IF THE COURT APPROVES THE SETTLEMENT, YOU WILL BE FOREVER BARRED FROM PURSUING THE RELEASED CLAIMS.

Hyperfine, Inc. Launches Observational Study to Define New Imaging Paradigm in Stroke Care

Retrieved on: 
Martedì, Luglio 11, 2023
Health, Medical Devices, Neurology, Radiology, Clinical Trials, Research, Science, Stroke, CT, University, PMR, Workflow, Ohio State University Wexner Medical Center, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, American Academy, Buffalo, Multimedia, Thrombectomy, MRI, Hospital, Patient, Diagnosis, FDA, Massachusetts General Hospital, ACTION, Hyperfine structure, Medical imaging, Pharmaceutical industry, Inc.

To support its acute stroke care initiatives, Hyperfine Inc. has formed an advisory board of world-renowned stroke experts.

Key Points: 
  • To support its acute stroke care initiatives, Hyperfine Inc. has formed an advisory board of world-renowned stroke experts.
  • View the full release here: https://www.businesswire.com/news/home/20230711397384/en/
    As a prospective, international, multi-site observational study, ACTION PMR aims to examine the integration of brain imaging with the Swoop® system into the stroke diagnosis and treatment workflow.
  • The goal is to use point-of-care brain imaging to identify strokes and viable brain tissue that can be saved.
  • However, the limited availability of MRI scanners near acute care settings in many hospitals highlights the need for point-of-care MR brain imaging.

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Retrieved on: 
Martedì, Giugno 27, 2023
Lead, ONC201, Retirement, Patient, Chairperson, ACTION, Chair, Management

DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President and Chief Executive Officer of Chimerix and his appointment to the Board of Directors. Mr. Andriole replaces Mike Sherman, who is retiring from his role as Chief Executive Officer and will become Chairman of the Board of Directors. Martha Demski, the current Board Chair, will assume the role of Lead Independent Director. These appointments will be effective on August 1, 2023.

Key Points: 
  • DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President and Chief Executive Officer of Chimerix and his appointment to the Board of Directors.
  • Mr. Andriole replaces Mike Sherman, who is retiring from his role as Chief Executive Officer and will become Chairman of the Board of Directors.
  • Martha Demski, the current Board Chair, will assume the role of Lead Independent Director.
  • “The Board has been thoughtful in planning this succession, ensuring ongoing strong leadership with the continuity of an accomplished management team,” said Martha Demski, Board Chair of Chimerix.

Postal Service Honors Congressman John Lewis on New Forever Stamp

Retrieved on: 
Giovedì, Giugno 22, 2023
The Postal Service, Pinterest, Collection, United States Postal Service, Legislation, Newsroom, Violence, Face, Post, Atlanta City Council, Selma to Montgomery National Historic Trail, Nashville Student Movement, Peace, Peace Corps, History, National Mall, Wind, Sale, Lewis, United, Civil Rights Act, Congress, Post office, USPS, Book, Student Nonviolent Coordinating Committee, Representative, Walking, VISTA, Presidential Medal of Freedom, Voter Education Project, Culture, Louisiana House of Representatives, Mail, House, Civil Rights Act of 1964, ACTION, History of the United States, Conscience, Amazon

The words "USA" and "Forever" appear in the stamp's top left corner.

Key Points: 
  • The words "USA" and "Forever" appear in the stamp's top left corner.
  • Derry Noyes, an art director for USPS, designed the stamp.
  • The Postal Service generally receives no tax dollars for operating expenses and relies on the sale of postage, products and services to fund its operations.
  • For more information about the Postal Service, visit usps.com and facts.usps.com .

Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd line Hodgkin Lymphoma

Retrieved on: 
Venerdì, Giugno 16, 2023
Well, Hodgkin lymphoma, Cytokine release syndrome, CRS, Associate professor, Lymphoma, Malignancy, EOT, CHL, TT11, MD Anderson Cancer Center, International Conference on Population and Development, ASCT, Patient, Risk, University, PET/CT, Neoplasm, Therapy, CD30, ACTION, Conference, End, Safety, Bone marrow, Pharmaceutical industry, Medical imaging, Nivolumab

TT11 is currently being investigated in combination with Nivolumab in Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients after frontline therapy failure (NCT05352828).

Key Points: 
  • TT11 is currently being investigated in combination with Nivolumab in Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients after frontline therapy failure (NCT05352828).
  • Study protocol involves patients being treated with 2 cycles of Nivolumab, followed by a single infusion of CD30.CAR-T preceded by lymphodepletion (LD) chemotherapy.
  • A total of 15 patients were enrolled of which 13 were treated with Nivolumab + CD30 CAR-T therapy.
  • These results offer the potential to re-define Hodgkin lymphoma treatment paradigm, offering a second line treatment alternative free of transplant and high dose chemotherapy to patients who fail frontline therapy,” said Thomas Willemsen, President and CEO, Tessa Therapeutics.